Vascular Disruption Without Systemic Toxicity: How EBC-46 Starves Tumours From Within
EBC-46 destroys the blood vessels feeding a tumour within hours of injection — cutting off oxygen and nutrients while leaving surrounding healthy vasculature intact. Here is the biology behind this precision.
The Tumour's Achilles Heel: Its Blood Supply
Every solid tumour depends on angiogenesis — the formation of new blood vessels — to sustain its growth. Without a dedicated blood supply, tumours cannot grow beyond a few millimetres in diameter. This fundamental dependency is what makes vascular disruption such a powerful therapeutic strategy, and it is one of the primary mechanisms through which tigilanol tiglate (EBC-46) eliminates tumours.[1]
What distinguishes EBC-46 from systemic anti-angiogenic drugs like bevacizumab is the speed and precision of its action. Injected directly into the tumour, EBC-46 triggers catastrophic vascular collapse within hours — a timeline that reflects the potency of its PKC-mediated signalling cascade.[2]
PKC Activation and Endothelial Cell Response
EBC-46 is a diacylglycerol analogue that binds with high affinity to the C1 regulatory domain of protein kinase C (PKC), particularly the delta and epsilon isoforms.[3] When EBC-46 activates PKC in endothelial cells lining tumour blood vessels, it triggers a rapid sequence of events: increased vascular permeability, disruption of cell-cell junctions, and ultimately endothelial cell death.
The result is haemorrhagic necrosis — the tumour's blood vessels rupture and collapse, flooding the tumour microenvironment with blood components while simultaneously cutting off oxygen and nutrient delivery. This ischaemic injury alone is often sufficient to destroy a significant portion of the tumour mass.
Why Healthy Vessels Are Spared
A critical question for any vascular disrupting agent is selectivity: why does it destroy tumour vessels without causing widespread vascular damage? The answer lies in the fundamental differences between tumour neovasculature and normal blood vessels.[4]
Tumour blood vessels are structurally abnormal — they lack the smooth muscle coverage and basement membrane integrity of mature vessels. They are also characterised by chaotic branching, variable diameter, and incomplete endothelial cell junctions. These structural defects make tumour vessels inherently more vulnerable to PKC-mediated disruption. Normal vessels, with their mature architecture and robust support structures, can withstand the same signalling cascade without catastrophic failure.
The Three-Phase Destruction Sequence
Preclinical and clinical observations suggest EBC-46 kills tumours through three overlapping phases:[5]
- Phase 1 — Vascular disruption (0–4 hours): Tumour blood vessels collapse, causing haemorrhagic necrosis and cutting off the tumour's metabolic lifeline.
- Phase 2 — Direct tumour cell death (4–24 hours): PKC activation in tumour cells triggers apoptotic and necrotic cell death pathways, compounding the ischaemic damage.
- Phase 3 — Immune recruitment (24–72 hours): Neutrophils and macrophages infiltrate the necrotic tumour bed, clearing debris and mounting an adaptive immune response against residual tumour cells.
This three-phase mechanism explains why EBC-46-treated tumours often show complete regression rather than partial response — each phase reinforces the others, creating a cascade that leaves little opportunity for tumour survival.[6]
Implications for Combination Therapy
The vascular disruption mechanism has significant implications for combining EBC-46 with other therapies. Checkpoint inhibitors, for instance, require immune cell infiltration of the tumour — something that EBC-46 actively promotes through its inflammatory cascade. The debris from vascular disruption and tumour necrosis releases tumour-associated antigens that can prime antigen-presenting cells, potentially converting the treated tumour into an in-situ vaccine.[7]
Understanding the vascular disruption component of EBC-46's mechanism is essential not only for optimising dosing and injection protocols but for designing rational combination strategies that exploit this unique mode of action.
References
- Boyle et al. (2014) Intratumoural injection of EBC-46 in canine tumours. PLOS ONE. PubMed ↗
- Newton (2018) PKC isoforms in cell signalling. Trends in Biochemical Sciences. PubMed ↗
- PKC-delta and epsilon isoform selectivity in diacylglycerol binding. PubMed ↗
- Boyle et al. (2014) Selectivity of vascular disruption in tumour models. PubMed ↗
- Panizza et al. (2019) Phase I clinical study of tigilanol tiglate. EBioMedicine. PubMed ↗
- De Ridder et al. (2021) Immune response following EBC-46 treatment. PubMed ↗
- PKC signalling and tumour immunogenicity. PubMed ↗
